Physician profile
Michael G May
NPI 1356345979
$5,880.84
in general payments reported to CMS, 2019-2025
33 companies · $15.66 in 2025
The $15.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $1,600 · 2021: $2,312 · 2022: $1,009 · 2023: $33.08 · 2024: $21.12 · 2025: $15.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $848.70 | 2019-2021 | |
| Abbvie INC. | $753.52 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $613.32 | 2019-2022 | |
| Amgen INC. | $580.22 | 2019-2022 | |
| Novo Nordisk INC | $560.72 | 2020-2023 | Ozempic, Rybelsus |
| Allergan, INC. | $241.01 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.99 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $192.59 | 2019-2022 | |
| Astellas Pharma US INC | $162.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $153.59 | 2019-2022 | |
| Pfizer INC. | $145.43 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $130.27 | 2021 | |
| Glaxosmithkline, LLC. | $128.87 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $127.99 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $123.63 | 2019-2021 | |
| Smith+Nephew, INC. | $112.61 | 2021-2025 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $71.81 | 2020-2021 | |
| Eisai INC. | $60.08 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $57.24 | 2021-2022 | |
| Shire North American Group INC | $55.34 | 2019 | |
| Lilly USA, LLC | $54.60 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.62 | 2022 | |
| Sunovion Pharmaceuticals INC. | $40.36 | 2020-2021 | |
| Amarin Pharma, INC. | $31.36 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $28.54 | 2020-2022 | |
| Medtronic, INC. | $18.77 | 2022 | |
| Boston Scientific Corporation | $15.31 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.34 | 2022 | |
| Seqirus USA INC | $12.67 | 2022 | |
| Melinta Therapeutics, LLC | $11.23 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.